iNtODEWORLD | Shrimp EMS (Early Mortality Syndrome) and its solution
17145
single,single-post,postid-17145,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

Shrimp EMS (Early Mortality Syndrome) and its solution

Global Shrimp Production Status Shrimp is a globally beloved food. Since it contains high-quality protein, calcium, minerals and vitamin B complexes, global demands for shrimps have constantly increased. Shrimps are mainly produced in China and Southeast Asia (Thailand, Vietnam and Indonesia), Latin America and India; more than 90% of the world’s shrimp is produced in these regions. As of 2016, world shrimp production is about 5 million tons; and it is expected to increase to 7 million tons by 2022 .1

EMS (Early Mortality Syndrome) EMS (Early Mortality Syndrome) or AHPND (Acute Hepatopancreatic Necrosis Disease) is the most problematic disease in the shrimp farming industry. It started in China in 2009, ramped up in Vietnam, Malaysia and Thailand in 2011 and costed more than $ 1 trillion.2 Recent discover showed that EMS is caused by bacteria called Vibrio parahaemolyticus. When young shrimp fry gets EMS, mortality rate goes up to 100% within 20 to 30 days. Because of this reason, global shrimp production has declined by 23% from 2013 to 2015, and many farms are still suffering from EMS.

Solution for EMS: Bacteriophage iNtRON Biotechnology is developing a total solution to treat shrimp EMS by utilizing bacteriophage which is the natural enemy of bacteria. With bacteriophage solution, iNtRON is promoting to enter the global market through collaboration with leading foreign companies. In addition to shrimp EMS, iNtRON is also focusing on other marine fisheries field such as halibut and salmon. iNtRON is using its novel platform technology of bacteriophage and endolysin in various field such as biopharmaceutical for superbugs, second hospital infection prevention, ballast water treatment, and livestock antibiotic replacement.

it is iNtRON.

[Reference]  1. Shrimp Market Report and Forecast 2017 – 2022 (EMR) 2. Zorriehzahra MJ, Banaederakhshan R (2015). Early mortality syndrome (EMS) as new emerging threat in shrimp industry. Adv. Anim. Vet. Sci. 3(2s): 64-72.



iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.